CUP-syndrome: Inguinal high grade serous ovarian carcinoma lymph node metastases with unknown primary origin - a case report and literature review.
cup syndrome
groin recurrence
high grade ovarian cancer
inguinal lymph node
recurrence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
07
2022
accepted:
15
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
High-grade serous ovarian carcinoma (HGSC) often presents lymph node involvement. According to the paths of lymphatic drainage, the most common site of nodal metastasis is in the aortic area. However, pelvic lymph nodes are also involved and inguinal metastases are less frequent. Our report concerns the case of a 78-year-old woman with an inguinal lymph node relapse of HGSC, with the prior positivity of a right inguinal lymph node, after the primary surgery. Ovaries and tubes were negative on histological examination. A comprehensive search of the literature published from January 2000 to October 2021 was conducted on PubMed and Scopus. The papers were selected following the PRISMA guidelines. Nine retrospective studies were evaluated. Overall, 67 studies were included in the initial search. Applying the screening criteria, 36 articles were considered eligible for full-text reading of which, after applying the exclusion criteria, 9 studies were selected for the final analysis and included in the systematic review. No studies were included for a quantitative analysis. We divided the results according to the relapse location: loco-regional, abdominal, and extra-abdominal recurrence. Inguinal node metastasis is a rare but not unusual occurrence in HGSC. A reasonable level of suspicion should be maintained in patients with inguinal adenopathy and high CA125 values, especially in women with a history of gynecologic surgery, even in the absence of negative imaging for an ovarian origin.
Identifiants
pubmed: 36300091
doi: 10.3389/fonc.2022.987169
pmc: PMC9589412
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
987169Informations de copyright
Copyright © 2022 Restaino, Mauro, Zermano, Pellecchia, Mariuzzi, Orsaria, Titone, Biasioli, Della Martina, Andreetta, Poletto, Arcieri, Buda, Driul and Vizzielli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2006 Nov;7(11):925-34
pubmed: 17081918
Anticancer Res. 2015 Dec;35(12):6951-5
pubmed: 26637921
Gynecol Oncol. 2007 Jan;104(1):41-5
pubmed: 16952391
Ann Acad Med Singap. 2007 Jun;36(6):427-30
pubmed: 17597969
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Gynecol Oncol. 1991 Feb;40(2):103-6
pubmed: 2010101
In Vivo. 2018 Mar-Apr;32(2):385-389
pubmed: 29475925
Int J Gynecol Cancer. 2015 Oct;25(8):1405-14
pubmed: 26397066
Arch Gynecol Obstet. 2014 May;289(5):1087-92
pubmed: 24213097
Int J Mol Sci. 2020 Jul 07;21(13):
pubmed: 32646060
BMC Cancer. 2008 Dec 12;8:367
pubmed: 19077269
Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):529-51
pubmed: 12413933
Am Fam Physician. 2016 Jun 1;93(11):937-44
pubmed: 27281838
Int J Gynecol Cancer. 2009 Nov;19(8):1307-13
pubmed: 20009882
Gynecol Oncol. 1997 Jun;65(3):467-72
pubmed: 9190977
Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1238-44
pubmed: 17433064
Cancer. 1989 Oct 1;64(7):1508-13
pubmed: 2776109
J Ovarian Res. 2014 Feb 10;7:20
pubmed: 24506831
Ann Surg Oncol. 2014 Nov;21(12):3970-7
pubmed: 24849521
Int J Gynecol Pathol. 2013 Mar;32(2):167-70
pubmed: 23370643
Indian J Surg Oncol. 2016 Dec;7(4):436-440
pubmed: 27872532
Br J Cancer. 2006 Sep 18;95(6):699-704
pubmed: 16940979
Gynecol Oncol. 2006 Mar;100(3):621-2
pubmed: 16246401
Gynecol Oncol. 1993 Nov;51(2):150-4
pubmed: 8276287
Int J Surg Case Rep. 2020;66:277-282
pubmed: 31884264
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Int J Gynecol Cancer. 2010 Apr;20(3):341-5
pubmed: 20375794
Int J Gynecol Cancer. 2020 Nov;30(11):1803-1810
pubmed: 32895312
BMJ Case Rep. 2021 Apr 28;14(4):
pubmed: 33910789
Curr Treat Options Oncol. 2016 Jan;17(1):3
pubmed: 26739150
Ann Transl Med. 2020 Dec;8(24):1709
pubmed: 33490221
Cancer Lett. 2020 Apr 28;476:152-160
pubmed: 32067992
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
Minerva Med. 2019 Aug;110(4):367-384
pubmed: 31124637
Am J Obstet Gynecol. 2019 Sep;221(3):245.e1-245.e15
pubmed: 31055034
J Egypt Natl Canc Inst. 2017 Jun;29(2):109-114
pubmed: 28258913